Citation Impact 2023
Journal Impact Factor: 4.4
5-year Journal Impact Factor: 4.9
Source Normalized Impact per Paper (SNIP): 1.294
SCImago Journal Rank (SJR): 1.518
Speed 2023
Submission to first editorial decision (median days): 9
Submission to acceptance (median days): 111
Usage 2023
Downloads: 3,331,819
Altmetric mentions: 1,885
Articles
Page 117 of 155
-
Citation: Arthritis Research & Therapy 2005 7:126
-
The differential contribution of tumour necrosis factor to thermal and mechanical hyperalgesia during chronic inflammation
Therapies directed against tumour necrosis factor (TNF) are effective for the treatment of rheumatoid arthritis and reduce pain scores in this condition. In this study, we sought to explore mechanisms by which...
Citation: Arthritis Research & Therapy 2005 7:R807 -
Tumor necrosis factor-α blockade in ankylosing spondylitis: a potent but expensive anti-inflammatory treatment or true disease modification?
Blocking tumor necrosis factor-α either with monoclonal antibodies or with soluble receptor constructs has been proven to be effective with an acceptable safety profile in patients with rheumatoid arthritis, a...
Citation: Arthritis Research & Therapy 2005 7:121 -
Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score
Frequent assessments of rheumatoid arthritis (RA) disease activity allow timely adaptation of therapy, which is essential in preventing disease progression. However, values of acute phase reactants (APRs) are ...
Citation: Arthritis Research & Therapy 2005 7:R796 -
Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin
Pathological processes involved in the initiation of rheumatoid synovitis remain unclear. We undertook the present study to identify immune and stromal processes that are present soon after the clinical onset ...
Citation: Arthritis Research & Therapy 2005 7:R784 -
Role of regulatory T cells in experimental arthritis and implications for clinical use
CD4+CD25+ T regulatory cells are avidly studied because they modulate immune responses. Their possible role in autoimmunity and more specifically in rheumatoid arthritis (RA) has been highlighted by a string of r...
Citation: Arthritis Research & Therapy 2005 7:118 -
Microsomal prostaglandin E synthase-1: the inducible synthase for prostaglandin E2
Microsomal prostaglandin E synthase-1 (mPGES-1) is an inducible enzyme that catalyzes the conversion of prostaglandin (PG)H2 to PGE2. Proinflammatory stimuli markedly increase levels of mPGES-1 expression both in...
Citation: Arthritis Research & Therapy 2005 7:114 -
Mithramycin downregulates proinflammatory cytokine-induced matrix metalloproteinase gene expression in articular chondrocytes
Interleukin-1 (IL-1), IL-17 and tumor necrosis factor alpha (TNF-α) are the main proinflammatory cytokines implicated in cartilage breakdown by matrix metalloproteinase (MMPs) in arthritic joints. We studied t...
Citation: Arthritis Research & Therapy 2005 7:R777 -
A monoclonal antibody against kininogen reduces inflammation in the HLA-B27 transgenic rat
The human leukocyte antigen B27 (HLA-B27) transgenic rat is a model of human inflammatory bowel disease, rheumatoid arthritis and psoriasis. Studies of chronic inflammation in other rat models have demonstrate...
Citation: Arthritis Research & Therapy 2005 7:R769 -
Chondrocytes, synoviocytes and dermal fibroblasts all express PH-20, a hyaluronidase active at neutral pH
Hyaluronan (HA), an important component of connective tissues, is highly metabolically active, but the mechanisms involved in its catabolism are still largely unknown. We hypothesized that a protein similar to...
Citation: Arthritis Research & Therapy 2005 7:R756 -
Serum protein profile in systemic-onset juvenile idiopathic arthritis differentiates response versus nonresponse to therapy
Systemic-onset juvenile idiopathic arthritis (SJIA) is a disease of unknown etiology with an unpredictable response to treatment. We examined two groups of patients to determine whether there are serum protein...
Citation: Arthritis Research & Therapy 2005 7:R746 -
Dermatological conditions during TNF-α-blocking therapy in patients with rheumatoid arthritis: a prospective study
Various dermatological conditions have been reported during tumor necrosis factor (TNF)-α-blocking therapy, but until now no prospective studies have been focused on this aspect. The present study was set up t...
Citation: Arthritis Research & Therapy 2005 7:R666 -
The role of interleukin-1 in the pathogenesis of human Intervertebral disc degeneration
In this study, we investigated the hypotheses that in human intervertebral disc (IVD) degeneration there is local production of the cytokine IL-1, and that this locally produced cytokine can induce the cellula...
Citation: Arthritis Research & Therapy 2005 7:R732 -
Dynamic magnetic resonance of the wrist in psoriatic arthritis reveals imaging patterns similar to those of rheumatoid arthritis
This dynamic magnetic resonance imaging (MRI) study is concerned with a prospective evaluation of wrist synovitis in patients with psoriatic arthritis (PsA) in comparison with patients with rheumatoid arthriti...
Citation: Arthritis Research & Therapy 2005 7:R725 -
Regeneration of the immunoglobulin heavy-chain repertoire after transient B-cell depletion with an anti-CD20 antibody
B-cell depletive therapies have beneficial effects in patients suffering from rheumatoid arthritis. Nevertheless, the role of B cells in the pathogenesis of the disease is not clear. In particular, it is not k...
Citation: Arthritis Research & Therapy 2005 7:R714 -
Clinical evaluation of autoantibodies to a novel PM/Scl peptide antigen
Anti-PM/Scl antibodies represent a specific serological marker for a subset of patients with scleroderma (Scl) and polymyositis (PM), and especially with the PM/Scl overlap syndrome (PM/Scl). Anti-PM/Scl react...
Citation: Arthritis Research & Therapy 2005 7:R704 -
The active metabolite of leflunomide, A77 1726, interferes with dendritic cell function
Leflunomide, a potent disease-modifying antirheumatic drug used in the treatment of rheumatoid arthritis (RA), exhibits anti-inflammatory, antiproliferative and immunosuppressive effects. Although most of the ...
Citation: Arthritis Research & Therapy 2005 7:R694 -
The determinants of change in tibial plateau bone area in osteoarthritic knees: a cohort study
Bone is integral to the pathogenesis of osteoarthritis (OA). Whether the bone area of the tibial plateau changes over time in subjects with knee OA is unknown. We performed a cohort study to describe this and ...
Citation: Arthritis Research & Therapy 2005 7:R687 -
Intra-articular injections of high-molecular-weight hyaluronic acid have biphasic effects on joint inflammation and destruction in rat antigen-induced arthritis
To assess the potential use of hyaluronic acid (HA) as adjuvant therapy in rheumatoid arthritis, the anti-inflammatory and chondroprotective effects of HA were analysed in experimental rat antigen-induced arth...
Citation: Arthritis Research & Therapy 2005 7:R677 -
Gastrin-releasing peptide, substance P and cytokines in rheumatoid arthritis
Many studies have shown that modulation of cytokine function is effective in ameliorating symptoms of rheumatoid arthritis. Neuropeptides have recently been shown to have powerful effects on the production and...
Citation: Arthritis Research & Therapy 2005 7:111 -
Negative regulation of cytokine signaling and immune responses by SOCS proteins
Immune and inflammatory systems are controlled by multiple cytokines, including interleukins and interferons. Many of these cytokines exert their biological functions through JAKs (Janus tyrosine kinases) and ...
Citation: Arthritis Research & Therapy 2005 7:100 -
Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports
The objective was to improve understanding of adverse events occurring with celecoxib in the treatment of osteoarthritis and rheumatoid arthritis. Data were extracted from company clinical trial reports of ran...
Citation: Arthritis Research & Therapy 2005 7:R644 -
Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis
Cardiovascular event rates are markedly increased in rheumatoid arthritis (RA), and RA atherogenesis remains poorly understood. The relative contributions of traditional and nontraditional risk factors to card...
Citation: Arthritis Research & Therapy 2005 7:R634 -
Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173]
To determine the efficacy and safety of risedronate in patients with knee osteoarthritis (OA), the British study of risedronate in structure and symptoms of knee OA (BRISK), a 1-year prospective, double-blind,...
Citation: Arthritis Research & Therapy 2005 7:R625 -
Erratum to: Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab
Citation: Arthritis Research & Therapy 2005 7:113 -
Increased serum HO-1 in hemophagocytic syndrome and adult-onset Still's disease: use in the differential diagnosis of hyperferritinemia
Heme oxygenase-1 (HO-1), an inducible heme-degrading enzyme, is expressed by macrophages and endothelial cells in response to various stresses. Because ferritin synthesis is stimulated by Fe2+, which is a product...
Citation: Arthritis Research & Therapy 2005 7:R616 -
CD134 as target for specific drug delivery to auto-aggressive CD4+T cells in adjuvant arthritis
T cells have an important role during the development of autoimmune diseases. In adjuvant arthritis, a model for rheumatoid arthritis, we found that the percentage of CD4+ T cells expressing the activation marker...
Citation: Arthritis Research & Therapy 2005 7:R604 -
Anti-Sa antibodies and antibodies against cyclic citrullinated peptide are not equivalent as predictors of severe outcomes in patients with recent-onset polyarthritis
The prognostic value of two antibodies targeting citrullinated antigens, anti-Sa and anti-cyclic citrullinated peptide (CCP), present at inclusion, was evaluated prospectively in a cohort of 165 consecutive pa...
Citation: Arthritis Research & Therapy 2005 7:R592 -
The evolving clinical profile of abatacept (CTLA4–Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritis
Abatacept (CTLA4–Ig) is a novel fusion protein designed to modulate the T cell co-stimulatory signal mediated through the CD28–CD80/86 pathway. Clinical trials have provided preliminary evidence of the efficac...
Citation: Arthritis Research & Therapy 2005 7(Suppl 2):S21 -
Modulating co-stimulation: a rational strategy in the treatment of rheumatoid arthritis?
Rheumatoid arthritis (RA) is a common destructive inflammatory disease that affects 0.5–1% of the population in many countries. Even though several new treatments have been introduced for patients with RA, a c...
Citation: Arthritis Research & Therapy 2005 7(Suppl 2):S15 -
The role of the T cell in autoimmune inflammation
T cells, in particular CD4+ T cells, have been implicated in mediating many aspects of autoimmune inflammation. However, current evidence suggests that the role played by CD4+ T cells in the development of rheuma...
Citation: Arthritis Research & Therapy 2005 7(Suppl 2):S4 -
The science of rheumatoid arthritis: a prelude
Citation: Arthritis Research & Therapy 2005 7(Suppl 2):S1 -
Regulatory T cells in rheumatoid arthritis
Apart from the deletion of autoreactive T cells in the thymus, various methods exist in the peripheral immune system to control specific human immune responses to self-antigens. One of these mechanisms involve...
Citation: Arthritis Research & Therapy 2005 7:93 -
Signalling pathway involved in nitric oxide synthase type II activation in chondrocytes: synergistic effect of leptin with interleukin-1
The objective of the present study was to investigate the effect of leptin, alone or in combination with IL-1, on nitric oxide synthase (NOS) type II activity in vitro in human primary chondrocytes, in the mouse ...
Citation: Arthritis Research & Therapy 2005 7:R581 -
Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis
At present only few biological data are available to indicate whether psoriatic arthritis (PsA) is part of the spondyloarthropathy (SpA) concept, whether it is a separate disease entity or a heterogeneous dise...
Citation: Arthritis Research & Therapy 2005 7:R569 -
Proliferation and differentiation potential of chondrocytes from osteoarthritic patients
Autologous chondrocyte transplantation (ACT) has been shown, in long-term follow-up studies, to be a promising treatment for the repair of isolated cartilage lesions. The method is based on an implantation of in ...
Citation: Arthritis Research & Therapy 2005 7:R560 -
Quantitative ultrasound can assess the regeneration process of tissue-engineered cartilage using a complex between adherent bone marrow cells and a three-dimensional scaffold
Articular cartilage (hyaline cartilage) defects resulting from traumatic injury or degenerative joint disease do not repair themselves spontaneously. Therefore, such defects may require novel regenerative stra...
Citation: Arthritis Research & Therapy 2005 7:R552 -
Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey
The development of drug-induced lupus remains a matter of concern in patients treated with anti-tumour necrosis factor (TNF) alpha. The incidence of such adverse effects is unknown. We undertook a retrospectiv...
Citation: Arthritis Research & Therapy 2005 7:R545 -
Synovial microparticles from arthritic patients modulate chemokine and cytokine release by synoviocytes
Synovial fluid from patients with various arthritides contains procoagulant, cell-derived microparticles. Here we studied whether synovial microparticles modulate the release of chemokines and cytokines by fib...
Citation: Arthritis Research & Therapy 2005 7:R536 -
The mechanism of low-concentration sodium nitroprusside-mediated protection of chondrocyte death
Sodium nitroprusside (SNP), a widely used nitric oxide donor, has recently been shown to mediate chondrocyte apoptosis by generating reactive oxygen species, whereas more potent nitric oxide donors do not indu...
Citation: Arthritis Research & Therapy 2005 7:R526 -
ANKHvariants associated with ankylosing spondylitis: gender differences
The ank (progressive ankylosis) mutant mouse, which has a nonsense mutation in exon 12 of the inorganic pyrophosphate regulator gene (ank), exhibits aberrant joint ankylosis similar to human ankylosing spondyliti...
Citation: Arthritis Research & Therapy 2005 7:R513 -
Histone deacetylase inhibitors modulate metalloproteinase gene expression in chondrocytes and block cartilage resorption
Cartilage destruction in the arthritides is thought to be mediated by two main enzyme families: the matrix metalloproteinases (MMPs) are responsible for cartilage collagen breakdown, and enzymes from the ADAMT...
Citation: Arthritis Research & Therapy 2005 7:R503 -
The P2X7receptor is a candidate product of murine and human lupus susceptibility loci: a hypothesis and comparison of murine allelic products
Systemic lupus erythematosus and its murine equivalent, modelled in the New Zealand Black and New Zealand White (NZB × NZW)F1 hybrid strain, are polygenic inflammatory diseases, probably reflecting an autoimmune ...
Citation: Arthritis Research & Therapy 2005 7:R468 -
Citrullinated proteins have increased immunogenicity and arthritogenicity and their presence in arthritic joints correlates with disease severity
Autoantibodies directed against citrulline-containing proteins have an impressive specificity of nearly 100% in patients with rheumatoid arthritis and have been suggested to be involved in the disease pathogen...
Citation: Arthritis Research & Therapy 2005 7:R458 -
Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab
We analyzed the clinical response and the time to relapse after discontinuation of continuous long-term infliximab therapy in patients with ankylosing spondylitis (AS). After 3 years of infliximab therapy, all...
Citation: Arthritis Research & Therapy 2005 7:R439 -
The utility of pathway selective estrogen receptor ligands that inhibit nuclear factor-κB transcriptional activity in models of rheumatoid arthritis
Rheumatoid arthritis (RA) is a chronic inflammatory disease that produces synovial proliferation and joint erosions. The pathologic lesions of RA are driven through the production of inflammatory mediators in ...
Citation: Arthritis Research & Therapy 2005 7:R427 -
Peripheral blood but not synovial fluid natural killer T cells are biased towards a Th1-like phenotype in rheumatoid arthritis
Natural killer T (NKT) cells have been implicated in the regulatory immune mechanisms that control autoimmunity. However, their precise role in the pathogenesis of rheumatoid arthritis (RA) remains unclear. Th...
Citation: Arthritis Research & Therapy 2005 7:R493 -
A web tool for finding gene candidates associated with experimentally induced arthritis in the rat
Rat models are frequently used for finding genes contributing to the arthritis phenotype. In most studies, however, limitations in the number of animals result in a low resolution. As a result, the linkage bet...
Citation: Arthritis Research & Therapy 2005 7:R485 -
Small GTP-binding protein Rho-mediated signaling promotes proliferation of rheumatoid synovial fibroblasts
Rho is a major small GTP-binding protein that is involved in the regulation of various cell functions, including proliferation and cell migration, through activation of multiple signaling molecules in various ...
Citation: Arthritis Research & Therapy 2005 7:R476 -
Signal transduction in T lymphocytes
Citation: Arthritis Research & Therapy 2005 7(Suppl 1):S17